DTU Logo
Overview | 4-T | ACE | ADOPT | AFORRD | DREAM | EDIT | EXSCEL | FHS | GLINT | ISAT | LDS | NAVIGATOR | TECOS | UKPDS

A Diabetes Outcomes Progression Trial



News


Search news :

Rosiglitazone out-performs Metformin and Glyburide in terms of renal function as an early-stage type 2 diabetes treatment

19-Apr-2011
News Image ADOPT (A Diabetes Outcomes Prevention Trial) showed that initial treatment with just rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. In CJASN, we examine the differences in albumin excretion, renal function and blood pressure over the course of 5 years between the treatment groups....

[Read more...]

More effective glycaemic control seen with rosiglitazone is explained by effects on both β-cell function and insulin sensitivity

22-Mar-2011
News Image The ADOPT study (A Diabetes Outcomes Prevention Trial) showed that treatment with rosiglitazone alone provided somewhat more effective glycaemic control than metformin or glyburide alone, in patients with recently diagnosed type 2 diabetes. In a paper published recently in Diabetes, we examined changes in β-cell function and insulin sensitivity among the three treatments in ADOPT....

[Read more...]